Gablofen 1 mg/ml solution for injection/infusion
Adults Gablofen is indicated in patients with severe chronic spasticity resulting from trauma, multiple sclerosis or other spinal cord disorders, who are unresponsive to oral baclofen or other orally administered antispastic medicinal products and/or those patients who experience unacceptable side-effects at effective oral doses. Gablofen is effective in patients with severe chronic spasticity of cerebral origin, resulting e.g. from cerebral palsy, brain trauma or cerebrovascular accident. Paediatric population Gablofen is indicated in patients aged 4 to <18 years with severe chronic spasticity of spinal or cerebral origin (associated with injury, multiple sclerosis, or other spinal cord diseases) who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable undesirable effects at effective oral doses.